Skip to main content
NCBI home page
The Journal of Experimental Medicine logoLink to The Journal of Experimental Medicine
. 1968 Jan 31;127(2):371–386. doi: 10.1084/jem.127.2.371

THE DERIVATION OF TWO DISTINCT ANAPHYLATOXIN ACTIVITIES FROM THE THIRD AND FIFTH COMPONENTS OF HUMAN COMPLEMENT

C G Cochrane 1, H J Müller-Eberhard 1
PMCID: PMC2138443  PMID: 4383923

Abstract

Anaphylatoxin activity was derived from both human C'5 and C'3 molecules. This was achieved in the case of C'5 by interaction with trypsin or with EAC'4, oxy2a, 3. The smooth muscle-contracting material obtained from the treated C'5 was found to be a fragment of approximately 9,000–11,000 molecular weight. Its action was inhibited with antihistamine. The trypsinized C'5 also increased vascular permeability in guinea pig skin. When human C'3 was incubated with C'3 inactivator complex, which consists of a cobra venom protein and a β-globulin of human serum, anaphylatoxin activity was observed. The activity was associated with a fragment cleaved from the C'3 molecule, having a molecular weight of between 6,000 and 15,000 as determined by gel filtration techniques. Similar activity was derived from C'3 by the C'3-converting enzyme in free or in cell-bound form. The C'5 anaphylatoxin failed to cross-desensitize guinea pig ileum to the contracting capacities of C'3 and guinea pig anaphylatoxin and vice versa. Anaphylatoxin prepared from C'3 by all methods mentioned above caused cross-desensitization to the other C'3 derivatives, but failed to desensitize to guinea pig anaphylatoxin.

Full Text

The Full Text of this article is available as a PDF (906.9 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Cooper N. R., Becker E. L. Complement associated peptidase activity of guinea pig serum. I. Role of complement components. J Immunol. 1967 Jan;98(1):119–131. [PubMed] [Google Scholar]
  2. Dias Da Silva W., Lepow I. H. Complement as a mediator of inflammation. II. Biological properties of anaphylatoxin prepared with purified components of human complement. J Exp Med. 1967 May 1;125(5):921–946. doi: 10.1084/jem.125.5.921. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Jensen J. Anaphylatoxin in its relation to the complement system. Science. 1967 Mar 3;155(3766):1122–1123. doi: 10.1126/science.155.3766.1122. [DOI] [PubMed] [Google Scholar]
  4. MUELLER-EBERHARD H. J., BIRO C. E. ISOLATION AND DESCRIPTION OF THE FOURTH COMPONENT OF HUMAN COMPLEMENT. J Exp Med. 1963 Sep 1;118:447–466. doi: 10.1084/jem.118.3.447. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. McConahey P. J., Dixon F. J. A method of trace iodination of proteins for immunologic studies. Int Arch Allergy Appl Immunol. 1966;29(2):185–189. doi: 10.1159/000229699. [DOI] [PubMed] [Google Scholar]
  6. Müller-Eberhard H. J., Polley M. J., Calcott M. A. Formation and functional significance of a molecular complex derived from the second and the fourth component of human complement. J Exp Med. 1967 Feb 1;125(2):359–380. doi: 10.1084/jem.125.2.359. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Müllerèberhard H. J., Dalmasso A. P., Calcott M. A. The reaction mechanism of beta-1C-globulin (C'3) in immune hemolysis. J Exp Med. 1966 Jan 1;123(1):33–54. doi: 10.1084/jem.123.1.33. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. NILSSON U. R., MUELLER-EBERHARD H. J. ISOLATION OF BETA IF-GLOBULIN FROM HUMAN SERUM AND ITS CHARACTERIZATION AS THE FIFTH COMPONENT OF COMPLEMENT. J Exp Med. 1965 Aug 1;122:277–298. doi: 10.1084/jem.122.2.277. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. NORTON S. Quantitative determination of mast cell fragmentation by compound 48/80. Br J Pharmacol Chemother. 1954 Dec;9(4):494–497. doi: 10.1111/j.1476-5381.1954.tb00867.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Nilsson U. R., Müller-Eberhard H. J. Studies on the mode of action of the fifth, sixth and seventh component of human complement in immune haemolysis. Immunology. 1967 Jul;13(1):101–117. [PMC free article] [PubMed] [Google Scholar]
  11. OSLER A. G., RANDALL H. G., HILL B. M., OVARY Z. Studies on the mechanism of hypersensitivity phenomena. III. The participation of complement in the formation of anaphylatoxin. J Exp Med. 1959 Aug 1;110(2):311–339. doi: 10.1084/jem.110.2.311. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Polley M. J., Müller-Eberhard H. J. Enharncement of the hemolytic activity of the second component of human complement by oxidation. J Exp Med. 1967 Dec 1;126(6):1013–1025. doi: 10.1084/jem.126.6.1013. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. STEGEMANN H., HILLEBRECHT R., RIEN W. ZUR CHEMIE DES ANAPHYLATOXINS. Hoppe Seylers Z Physiol Chem. 1965;340:11–17. doi: 10.1515/bchm2.1965.340.1-2.11. [DOI] [PubMed] [Google Scholar]
  14. STEGEMANN H., VOGT W., FRIEDBERG K. D. UBER DIE NATUR DES ANAPHYLATOXINS. Hoppe Seylers Z Physiol Chem. 1964;337:269–276. doi: 10.1515/bchm2.1964.337.1.269. [DOI] [PubMed] [Google Scholar]
  15. Stegemann H., Bernhard G., O'Neil J. A. Endgruppen von Anaphylatoxin. Einfache Sequenzanalyse von Carboxyl-endständigen Aminosäuren. Hoppe Seylers Z Physiol Chem. 1964;339(1):9–13. [PubMed] [Google Scholar]
  16. da Silva W. D., Eisele J. W., Lepow I. H. Complement as a mediator of inflammation. 3. Purification of the activity with anaphylatoxin properties generated by interaction of the first four components of complement and its identification as a cleavage product of C'3. J Exp Med. 1967 Dec 1;126(6):1027–1048. doi: 10.1084/jem.126.6.1027. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from The Journal of Experimental Medicine are provided here courtesy of The Rockefeller University Press

RESOURCES